ArticleEBioMedicine2025
Safety, tolerability, immunogenicity, and plasmapheresis-based antibody collection in a phase 1b open label trial of two investigational monovalent chimpanzee adenoviral vectored filovirus vaccines, cAd3-Sudan and cAd3-Marburg, in healthy adults.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections.EBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSudan virus and Marburg virus are high priority biological threat pathogens with fatality rates of 25-90%. Recent outbreaks in Uganda, Equatorial Guinea, and Rwanda between 2022 and 2025 emphasise the critical need for effective vaccines. The aim of this phase 1b study was to determine clinical safety, tolerability, and immunogenicity of these monovalent vaccines. Plasmapheresis was used to collect hyper-immune plasma for use in future assay standardisation.
methodsParticipants received a single intramuscular injection of either cAd3-Sudan or cAd3-Marburg at 1 × 10
findingsThirty-two healthy adults were enrolled in the trial; the most commonly reported signs within 7 days of vaccination were mild headache and mild or moderate myalgia. No SAEs or deaths were reported. Binding antibodies (IgG) persisted at 9 weeks in all subjects in both groups; time to seroconversion was 14 days in both groups; peak IgG response across study participants was achieved by Day 29.
interpretationThese vaccines are safe, immunogenic and rapidly induced glycoprotein-specific antibody responses in all participants.
fundingFunding was provided by the Biomedical Advanced Research and Development Authority (BARDA), USA, under contract 75A50119C00055.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.